Phathom Pharmaceuticals (PHAT) EBT Margin (2023 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly EBT Margin of 37.69% for Q2 2026, up 17347.0% year-over-year from N/an in Q2 2025, and up 54.19% quarter-over-quarter from 82.28% in Q1 2026.
Phathom Pharmaceuticals (PHAT) EBT Margin (2023 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported EBT Margin for 4 consecutive years, with 37.69% the latest figure, recorded in Q2 2026.
- In Q2 2026, EBT Margin rose 17347.0% year-over-year to 37.69%; the TTM figure through Jun 2026 stood at 63.56% (up 21371.0% YoY), while the FY2025 annual figure was 261.87%, up 67502.0% from the prior year.
- EBT Margin climbed to 37.69% in Q2 2026 per PHAT's latest filing, from 82.28% in the prior quarter.
- Across five years, EBT Margin topped out at 36.72% in Q4 2025 and bottomed at 14060.85% in Q4 2023.
- Historically, EBT Margin has averaged 1931.17% across 4 years, with a median of 211.16% in 2025.
- Annual changes were most pronounced in 2024 — EBT Margin surged 1399416 bps — and 2025, when it jumped 2998 bps.
- Phathom Pharmaceuticals' EBT Margin stood at 14060.85% in 2023, then surged by 100 bps to 66.69% in 2024, then soared by 45 bps to 36.72% in 2025, then retreated by 3 bps to 37.69% in 2026.
- Business Quant data shows PHAT's EBT Margin at 37.69% in Q2 2026, 82.28% in Q1 2026, and 36.72% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | -37.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.69% |
| Mar 31, 2026 | -82.28% |
| Dec 31, 2025 | -17.63% |
| Sep 30, 2025 | -111.53% |
| Jun 30, 2025 | -211.16% |
| Mar 31, 2025 | -330.64% |
| Dec 31, 2024 | -251.15% |
| Sep 30, 2024 | -725.84% |
| Jun 30, 2024 | -1,248.50% |
| Mar 31, 2024 | -4,331.01% |
| Dec 31, 2023 | -9,539.59% |